The CLBP Treatment Gap: Why Opioid Alternatives Are Urgently Needed

Chronic low back pain (CLBP), defined as back pain persisting beyond 12 weeks, affects between 6.4% and 8.1% of the US population, with European non-specific CLBP prevalence approaching 23%. Despite this scale, the disease lacks a specific etiology in the majority of cases, forcing symptomatic rather than disease-modifying treatment strategies. Commonly used agents — NSAIDs, tricyclic antidepressants, muscle relaxants, and opioid analgesics — are explicitly noted in Pfizer patent filings as “not fully effective in many patients” and carry documented risks including gastrointestinal bleeding, somnolence, and cognitive impairment.

The opioid crisis has intensified demand for mechanistically distinct, non-addictive analgesics, creating substantial IP activity around nerve growth factor (NGF) antagonism, centralized pain pathways, and multi-target biologic approaches. According to WHO, musculoskeletal conditions including low back pain are the leading contributor to disability worldwide, underscoring the urgency of pipeline innovation in this space. The retrieved patent and literature dataset surveyed for this report spans anti-NGF antibodies, novel small molecule targets, centralized and neuropathic pain mechanisms, neuromodulation, and emerging combination strategies.

NGF/TrkA Antagonism: The Dominant Commercial Battlefield

Nerve growth factor (NGF) and its primary high-affinity receptor TrkA (NTRK1) represent the most extensively patent-covered targets in the CLBP drug pipeline. The mechanism involves blocking NGF from binding to TrkA and p75NTR receptors on nociceptors in the dorsal root ganglion (DRG) and peripheral tissue, thereby interrupting sensitization cascades that sustain chronic pain. TrkA activation triggers primary sensory neuron release of glutamate, ATP, substance P, and CGRP — providing a mechanistic rationale for the broad analgesic effect of anti-NGF agents that extends beyond simple peripheral blockade.

“Regeneron Pharmaceuticals holds at least 10 distinct anti-NGF patent filings across 9 jurisdictions — covering not only pain relief but the clinically powerful framing of ‘opioid addiction prevention,’ broadening the indication claim and the public health narrative.”

Regeneron Pharmaceuticals holds the largest single anti-NGF patent portfolio in this dataset, with filings spanning US, WO, EP, AU, NZ, JP, CA, SG, MY, MX, BR, CO, and PH jurisdictions. These cover compositions and methods for averting opioid addiction by substituting the anti-NGF antibody fasinumab for opioids in moderate-to-severe LBP patients. Pfizer holds parallel patent families in WO, CA, US, and JP jurisdictions covering CLBP treatment with anti-NGF antibodies, disclosing a specific dose of approximately 10 mg every 8 weeks via subcutaneous injection for tanezumab.

Earlier anti-NGF IP includes foundational filings from Rinat Neuroscience (now part of Pfizer) covering post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain. PanGenetics (Netherlands) and Abbott Research filed anti-NGF/TrkA blocking antibody IP for chronic pain with prolonged analgesic effect. Paradigm Biopharmaceuticals (Australia/Japan) extends the anti-NGF approach to polysulfated polysaccharides that modulate both mature NGF and pro-NGF.

A dual-target biologic approach also appears in this dataset. MedImmune (an AstraZeneca subsidiary) filed patents for bifunctional polypeptides containing both an NGF antagonist domain and a TNFα antagonist domain (soluble TNFR fragment), with the rationale that co-administration provides superior pain control versus either agent alone in preclinical models. A more recent filing from Immunomedics (a Gilead subsidiary) elaborates dosing regimens for such NGF/TNFα dual antagonists, signaling active prosecution of bispecific approaches.

Beyond NGF: Emerging Targets and Mechanistic Diversity in the CLBP Pipeline

The CLBP drug pipeline extends well beyond the NGF axis, with a diverse set of molecular targets reflecting the heterogeneous etiology of the condition. Eli Lilly has filed patents across WO, CA, AU, and JP jurisdictions for antibodies that bind both human TGF-alpha and human epiregulin — both ligands of the EGFR pathway — for the treatment of chronic nociceptive, neuropathic, and mixed pain including CLBP. The rationale is to address therapy-resistant chronic pain in patients who have failed two or more prior analgesic regimens, positioning this as a second-generation biologic approach for patients where NGF antagonists or NSAIDs have not achieved adequate control.

TNF inhibitors represent another established target in this dataset. Early patent filings by A+ Science Invest AB and inventor Kjell Olmarker (WO, AU, 2002) describe TNF inhibitors for LBP specifically attributed to local irritation of annulus-related nerve fibers by disc-derived substances — a disc-centric anti-inflammatory mechanism distinct from systemic inflammatory arthritis. Later dual-target NGF/TNFα combination patents demonstrate persistent commercial interest in TNFα as a pain mediator, particularly in the context of annular disc pathology.

Novel small molecule and nucleic acid approaches add further mechanistic diversity. Grünenthal GmbH filed patents for substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 (Kv7.2/7.3) modulators — voltage-gated potassium channels expressed in sensory neurons whose opening reduces neuronal excitability. West China Hospital of Sichuan University filed a patent for siRNA/shRNA nucleic acid drugs targeting NALCN (sodium leak channel, non-selective) for neuropathic and inflammatory chronic pain, formulated in liposomes, cationic polymer micelles, or AAV vectors, claiming a longer duration of analgesic effect compared to small molecules. As noted by NIH, ion channel modulation remains one of the most actively investigated non-opioid analgesic mechanisms, and the NALCN and KCNQ2/3 targets represent relatively uncontested IP territory within this dataset.

AnGes, Inc. (Japan/Canada) filed a patent for double-stranded oligonucleotide decoys capable of binding NF-κB and STAT6 transcription factor DNA binding sites for treatment of intervertebral disc degeneration, spinal pain, and proteoglycan synthesis promotion — a dual transcription factor targeting approach that addresses both inflammatory signaling and disc matrix biology simultaneously. Cannabinoid approaches also appear, with Vertanical GmbH (WO, 2025) filing for a composition containing delta-9-tetrahydrocannabinol (THC) combined with alpha-bisabolol, guaiol, beta-caryophyllene, and additional terpenes for CLBP, and Johns Hopkins University filing for cannabinoid-dendrimer conjugates targeting CB1/CB2 receptors on neurons and activated microglia.

Central Sensitization and the CNS-Targeted Opportunity in Chronic Back Pain

A growing body of patent activity signals recognition that CLBP in a subset of patients is driven by central neuronal sensitization rather than peripheral inflammation — and that this phenotype requires CNS-acting agents distinct from current anti-inflammatory or anti-nociceptive approaches. This represents a mechanistically underexploited opportunity in the retrieved patent landscape.

Medicon Pharmaceuticals holds active patents (CN, WO) covering sulindac phosphate (PS) — a non-COX-inhibiting sulindac metabolite — for treatment of pain associated with central sensitization, including neuropathic pain forms. The mechanistic claim is that PS acts directly on CNS neurons involved in sustained pain signaling, distinct from peripheral anti-inflammatory activity. This modality uses an NSAID-derived scaffold without COX inhibition, addressing the centrally sensitized pain phenotype without the gastrointestinal risks of conventional NSAIDs.

Apkarian Technologies LLC (linked to academic work from Northwestern University) holds US, WO, and CA patents on dopaminergic-analgesic combinations — specifically D1 or D2 receptor agonists combined with analgesics at low dopaminergic-to-analgesic ratios — to prevent the transition from acute to chronic back pain. One specific combination studied is levodopa/carbidopa plus naproxen (LDP+NPX). A 72-participant double-blind, placebo-controlled trial (59 completers) of this oral combination over 12 weeks in subacute back pain patients at risk for chronification is described within the patent text, reporting superior efficacy in females with greater than 80% pain relief in that subgroup. This approach is conceptually distinct from treating established CLBP: it targets a unique window in the pain trajectory to interrupt chronification.

“The dopaminergic-analgesic combination approach targets a unique window in the pain trajectory — interrupting the acute-to-chronic transition rather than treating established CLBP, representing a mechanistic and commercial differentiation from the mainstream anti-NGF pipeline.”

A University of California WO patent (2022) describes NAAA (N-acylethanolamine acid amidase) inhibition as a mechanism to halt consolidation of chronic pain states, differentiating this from gabapentin, ketamine, ketoprofen, and morphine, which failed in the same preclinical model. NuvaMid SA filed a US patent (2023) for nicotinamide mononucleotide (NMN) as a treatment and prevention strategy for chronic lumbalgia, representing a metabolic and mitochondrial approach to CLBP that is mechanistically novel within this dataset. Genomic biomarker research from McGill University identifies CNS, musculoskeletal, and immune gene networks in back pain GWAS, with equal neuronal and immunological etiology for pain susceptibility — a finding with implications for patient stratification in centralized pain phenotyping.

The US Department of Veterans Affairs holds precision medicine for pain biomarker patents disclosing diagnostic biomarker panels including HTR2A, EDN1, PNOC (prepronociceptin), and CALCA for pain state identification and pharmacogenomic-guided treatment selection. Regeneron’s 2025 OA proteomics patent introduces a weighted protein expression risk score to identify patients most likely to respond to NGF antagonist therapy, suggesting emerging patient stratification approaches that could be extended to CLBP. As reported by OECD, precision medicine frameworks that match patients to therapies based on biomarker profiles are increasingly central to drug development strategy in complex pain conditions.

Assignee Landscape and Clinical Signals: Who Is Filing and What Stage Are They At?

Patent activity in the CLBP drug pipeline is heavily concentrated among a small number of large pharmaceutical and biotechnology firms, with academic and government institutions contributing primarily through literature and a limited number of patents. Regeneron Pharmaceuticals and Pfizer dominate the anti-NGF space, while Eli Lilly occupies a differentiated position with EGFR-pathway biologics. Smaller biotechs — AnGes, Medicon Pharmaceuticals, Apkarian Technologies, and Grünenthal — hold novel mechanistic IP in less contested areas.

Multiple explicit clinical signals are embedded within the retrieved patent and literature dataset. Tanezumab (Pfizer) clinical trial data is cited within the Pfizer OA patent, referencing multiple published randomized clinical trials in OA and CLBP — including Brown et al. (J Pain 2012, Arthritis Rheum 2013) and Gimbel et al. (Pain 2014) — as demonstrating clinically meaningful improvements in pain reduction, physical function, and Patient’s Global Assessment. Fasinumab (Regeneron) is described in the CA patent as having “the potential to be effective in modulating NGF-associated pain without some of the adverse side effects of other analgesic medications,” with clinical-stage context implied through specific dosing parameters and patient history criteria requiring inadequate response to prior analgesics.

A non-randomized controlled clinical trial (22 acute LBP, 25 chronic LBP, 24 controls) measured TNFα, IL-1β, IL-6, IL-2, and IFN-γ production before and after 6 spinal manipulative therapy (SMT) sessions over 2 weeks, providing clinical biomarker data for inflammatory modulation by a non-pharmacological intervention. An observational study (n=35) of ultra-micronized palmitoylethanolamide (Normast) as add-on to tapentadol/pregabalin in failed back surgery syndrome reported pain improvement on VAS at 1, 2, and 3 months. Mesoblast International disclosed methods using mesenchymal lineage precursor or stem cells (MLPSCs) to reduce pain and decrease opioid use in chronic pain patients, including claims for improved EQ-5D quality-of-life scores. According to EMA, opioid-sparing endpoints are increasingly accepted as clinically meaningful outcomes in chronic pain trials, which aligns with the framing of multiple Regeneron and Mesoblast patent claims.

Neuromodulation device-based approaches also appear in this dataset. Relievant Medsystems, Inc. (IL, AU) filed patents for AI-based patient selection systems to predict favorable response to spinal neuromodulation procedures, including basivertebral nerve ablation, for CLBP stemming from vertebral bodies or endplates. Kyphon SARL (US) holds earlier patents for chemical denervation agents targeting the basivertebral nerve with both immediate and sustained-release formulations. Neuro Rehab Systems, LLC (US) filed for electrical stimulation of spinal stabilization muscle peripheral nerves via implanted or external pulse generators. No retrieved results contain language indicating regulatory approval decisions or final clinical trial outcomes for the biologics in the CLBP indication specifically.

Strategic Implications for Drug Developers and IP Teams

The CLBP drug pipeline presents a set of distinct strategic positions for drug developers, IP counsel, and R&D leaders. Anti-NGF antibody IP remains the dominant commercial battlefield for non-opioid CLBP biologics, with Regeneron and Pfizer holding extensive multi-jurisdictional portfolios covering not only pain relief but the clinically and commercially powerful framing of opioid addiction prevention — broadening the indication claim and public health narrative. IP strategists should monitor continuation filings and patient stratification claims as differentiating IP as the anti-NGF class matures.

Eli Lilly’s dual TGF-alpha/epiregulin antibody approach represents a second-wave differentiation from the NGF axis, targeting therapy-resistant chronic pain patients who have failed NGF or NSAID monotherapy. This positions the asset to address a failure mode of the first generation of anti-NGF biologics, particularly if safety concerns — such as arthropathy signals associated with NGF antibodies — restrict the addressable population. The EGFR-pathway biologic approach occupies relatively uncontested IP space compared to the crowded NGF landscape.

Central sensitization is an underexploited mechanistic opportunity in the retrieved patent landscape. Medicon Pharmaceuticals’ sulindac phosphate claims and the emerging NAAA and NALCN nucleic acid data signal growing recognition that CLBP with central sensitization features may require CNS-acting agents distinct from current anti-inflammatory or anti-nociceptive approaches. Drug developers focusing on centralized pain phenotyping tools and matched therapeutics could occupy relatively uncontested IP space. Patient stratification and precision medicine tools — proteomic risk scores, genomic biomarkers, AI-based neuromodulation candidate prediction — are emerging as IP-protectable assets adjacent to the therapeutic pipeline, suggesting that combination product and diagnostic strategies may become increasingly important in CLBP drug development. As documented by WIPO, combination product strategies that integrate diagnostics with therapeutics represent a growing category of patent filings in the biopharmaceutical sector globally.

Opioid sparing as a regulatory and commercial strategy is explicitly embedded in multiple Regeneron patent claims, the Mesoblast MLPSC data, and other pipeline assets. Framing CLBP agents within opioid-reduction narratives appears to be an active IP and commercial positioning strategy that may influence payer and regulatory interactions. For R&D teams seeking to map the full competitive landscape — including continuation filings, jurisdictional coverage gaps, and emerging patient stratification patents — PatSnap Eureka provides AI-powered analysis across the global patent database. Explore the full CLBP pipeline intelligence on PatSnap’s drug discovery platform.